Tafasitamab and other anti-CD19 monoclonal antibodies, as well as the anti-CD19 CAR T-cell therapy, are currently approved only for the treatment of patients with recurrent or refractory DLBCL. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.